DE60039160D1 - Verwendung von erbb-rezeptorliganden zur behandlung von diabetes - Google Patents

Verwendung von erbb-rezeptorliganden zur behandlung von diabetes

Info

Publication number
DE60039160D1
DE60039160D1 DE60039160T DE60039160T DE60039160D1 DE 60039160 D1 DE60039160 D1 DE 60039160D1 DE 60039160 T DE60039160 T DE 60039160T DE 60039160 T DE60039160 T DE 60039160T DE 60039160 D1 DE60039160 D1 DE 60039160D1
Authority
DE
Germany
Prior art keywords
erbb receptor
receptor ligands
diabetes
methods
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039160T
Other languages
English (en)
Inventor
Xiaojian Huang
Timothy Andrew Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE60039160D1 publication Critical patent/DE60039160D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
DE60039160T 1999-04-06 2000-04-05 Verwendung von erbb-rezeptorliganden zur behandlung von diabetes Expired - Lifetime DE60039160D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12801799P 1999-04-06 1999-04-06
PCT/US2000/009240 WO2000059525A2 (en) 1999-04-06 2000-04-05 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES

Publications (1)

Publication Number Publication Date
DE60039160D1 true DE60039160D1 (de) 2008-07-24

Family

ID=22433188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039160T Expired - Lifetime DE60039160D1 (de) 1999-04-06 2000-04-05 Verwendung von erbb-rezeptorliganden zur behandlung von diabetes

Country Status (12)

Country Link
US (2) US20060029605A1 (de)
EP (1) EP1165113B1 (de)
JP (1) JP4794049B2 (de)
AT (1) ATE397959T1 (de)
AU (1) AU4209300A (de)
CA (1) CA2368017A1 (de)
DE (1) DE60039160D1 (de)
DK (1) DK1165113T3 (de)
ES (1) ES2307505T3 (de)
IL (2) IL145674A0 (de)
PT (1) PT1165113E (de)
WO (1) WO2000059525A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
JP2008509093A (ja) * 2004-08-06 2008-03-27 ノヴォザイムズ グロペップ リミテッド 糖尿病治療法
WO2006128125A2 (en) * 2005-05-27 2006-11-30 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
CN101410509B (zh) * 2006-02-23 2016-05-18 维亚赛特公司 用于培养可分化细胞的组合物和方法
EP2094303A1 (de) 2006-12-22 2009-09-02 Novelix Therapeutics Gmbh Behandlung von diabetes mit mindestens einem für epidermalen wachstumsfaktor-rezeptor-spezifischen antikörper oder ein derivat davon
CN101735346B (zh) * 2008-11-07 2012-05-30 中国石油天然气股份有限公司 一种丙烯均聚和共聚的催化剂及其制备方法和应用
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CA3212301A1 (en) * 2013-02-06 2014-08-14 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
CA2919477A1 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
KR102027750B1 (ko) * 2018-05-03 2019-10-02 연세대학교 산학협력단 당 배출용 조성물
WO2021002645A1 (ko) * 2019-07-01 2021-01-07 연세대학교 산학협력단 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물
KR102109385B1 (ko) * 2019-08-21 2020-05-12 연세대학교 산학협력단 당 배출용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
JPH09511384A (ja) * 1994-01-24 1997-11-18 リサーチ トライアングル ファーマシューティカルズ リミテッド 若年型糖尿病の治療
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) * 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
JP3945846B2 (ja) * 1995-11-09 2007-07-18 武田薬品工業株式会社 膵臓機能改善剤
AU7506396A (en) * 1995-11-09 1997-05-29 Takeda Chemical Industries Ltd. Composition for improving pancreatic function
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis

Also Published As

Publication number Publication date
ES2307505T3 (es) 2008-12-01
EP1165113B1 (de) 2008-06-11
JP4794049B2 (ja) 2011-10-12
PT1165113E (pt) 2008-09-23
US20080031880A1 (en) 2008-02-07
ATE397959T1 (de) 2008-07-15
IL145674A0 (en) 2002-06-30
AU4209300A (en) 2000-10-23
CA2368017A1 (en) 2000-10-12
WO2000059525A2 (en) 2000-10-12
EP1165113A2 (de) 2002-01-02
JP2002541117A (ja) 2002-12-03
WO2000059525A3 (en) 2001-02-08
IL145674A (en) 2010-12-30
DK1165113T3 (da) 2008-09-08
US20060029605A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
ATE212230T1 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
ATE403680T1 (de) Herstellung tetravalenter antikörper
DE69737023D1 (de) Methode zur behandlung von krebs und pathogenen infektionen unter verwendung von antigen-präsentierenden zellen beladen mit rna
ATE361977T1 (de) In vitro verfahren zur induzierung der regulierten pankreatische-hormon produktion in nicht-pankreatischen inselngeweben, damit verbundene pharmazeutische zusammenseztzungen
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
SG160373A1 (en) Adult pancreatic derived stromal cells
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
DE60122337D1 (de) Verwendung von taci als antitumormittel
DK0804479T3 (da) Fremgangsmåde til behandling af diabetes mellitus ved anvendelse af KGF
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
SE0203594D0 (sv) Method for treatment of wood chips
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DE60234862D1 (de) Verfahren zur herstellung menschlicher beta-zelllinien
DE60037876D1 (de) Verfahren zur Herstellung von entwickelten und unentwickelten Pankreasendokrinezellen, Zellpräparat und Verwendung davon zur Behandlung von Diabetes
DE60132466D1 (de) Verfahren zur kultivierung von menschlichen lungenmastzellen und deren anwendungen
GB9907048D0 (en) Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
ATE357507T1 (de) Behandlung von menschlicher unfruchtbarkeit
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ATE535246T1 (de) Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems
ATE422668T1 (de) Verfahren zur identifizierung von modulatoren der glucoseaufnahme

Legal Events

Date Code Title Description
8364 No opposition during term of opposition